Crossmark

Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure

Crossref DOI link: https://doi.org/10.1038/s41409-023-02020-5

Published Online: 2023-06-26

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Novitzky-Basso, Igor https://orcid.org/0000-0003-3748-3117
Linn, Swe Mar

White, Jennifer

Elemary, Mohamed

Xenocostas, Anargyros

Deotare, Uday https://orcid.org/0000-0001-9391-4204
Kelly, Kate

Hamad, Nada https://orcid.org/0000-0001-7929-1450
Tan, Sui

Culos, Samantha

Law, Arjun https://orcid.org/0000-0002-9251-3609
Kumar, Rajat https://orcid.org/0000-0002-4786-5699
Mattsson, Jonas

Kim, Dennis Dong Hwan
License Information

Text and Data Mining valid from 2023-06-26

Version of Record valid from 2023-06-26
More Information

Article History

Received: 9 November 2022

Revised: 27 May 2023

Accepted: 13 June 2023

First Online: 26 June 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below